Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Aims: Overall survival (OS) and updated time to treatment failure (TTF) analysis of patients with EGFR mutation-positive (Del19, L858R) non-small-cell lung cancer who received sequential afatinib/osimertinib in the real-world GioTag study. Patients & methods: Patients had T790M-positive disease following first-line afatinib and received osimertinib treatment (n = 203). Primary outcome was TTF. The OS analysis was exploratory. Results: Median OS was 41.3 months (90% CI: 36.8–46.3) overall and 45.7 months (90% CI: 45.3–51.5) in patients with Del19-positive tumors (n = 149); 2-year survival was 80 and 82%, respectively. Updated median TTF with afatinib and osimertinib was 28.1 months (90% CI: 26.8–30.3). Conclusion: Sequential afatinib/osimertinib was associated with encouraging OS/TTF in patients with EGFR T790M-positive non-small-cell lung cancer, especially in patients with Del19-positive tumors. Trial registration number: NCT03370770
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The clinical effectiveness of afatinib has been confirmed by recent results of real-world studies.”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [99]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a global, noninterventional study of patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib in a real-world setting, which showed median time to treatment failure of 28.1 months (90% CI, 26.8–30.3) and median OS of 41.3 months (90% CI, 36.8–46.3).”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [99]
The cited source says what the claim attributes to it.
In the citing paper
“some data show that a sequential treatment strategy consisting of afatinib followed by osimertinib can provide a viable, long-term treatment option for patients who develop T790M-mediated resistance”
From Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings (2020) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1713137 · Cited by 5,508
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71173-8 · Cited by 1,574
Self-citationWu, Y.-L., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30608-3 · Cited by 1,216
Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J. C.-H., Lee, K. H., Lu, S., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30033-x · Cited by 1,183
Self-citationReck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Oxnard, G. R., Hu, Y., Mileham, K. F., Husain, H., Costa, D. B., Tracy, P., Feeney, N., Sholl, L. M., Dahlberg, S. E., Redig, A. J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.2969 · Cited by 686
Arcila, M. E., Oxnard, G. R., Nafa, K., Riely, G. J., Solomon, S. B., Zakowski, M. F., Kris, M. G., Pao, W., Miller, V. A., & Ladanyi, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2277 · Cited by 574
Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.3223 · Cited by 571
Self-citation
Cited by
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
Pottier, C., Fresnais, M., Gilon, M., Jérusalem, G., Longuespée, R., & Sounni, N. E. (2020) · Cancers · doi:10.3390/cancers12030731 · Cited by 515
Shah, R., & Lester, J. F. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.12.003 · Cited by 174
Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings
Harvey, R. D., Adams, V. R., Beardslee, T., & Medina, P. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220931926 · Cited by 115
Nazha, B., Yang, J. C., & Owonikoko, T. K. (2020) · Future Oncology · doi:10.2217/fon-2020-0951 · Cited by 84
Self-citationHochmair, M. J., Morabito, A., Hao, D., Yang, C., Soo, R. A., Yang, J. C., Gucalp, R. A., Halmos, B., Märten, A., & Čufer, T. (2020) · Future Oncology · doi:10.2217/fon-2020-0740 · Cited by 70
Self-citation
Metadata
- Authors
- Hochmair, M. J., Morabito, A., Hao, D., Yang, C.-T., Soo, R. A., Yang, J. C.-H., Gucalp, R., Halmos, B., Wang, L., Märten, A., & Cufer, T.
- Affiliations
- Ludwig Boltzmann Institute for Lung Health (AT)
- Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
- Tom Baker Cancer Center, Cummings School of Medicine, University of Calgary, Calgary, Alberta, Canada
- Chang Gung Memorial Hospital (TW)
- National University Hospital (SG)
- National Taiwan University Hospital (TW)
- Albert Einstein College of Medicine (US)
- Department of Oncology, Montefiore/Albert Einstein Cancer Center, Bronx, NY, USA
- Boehringer Ingelheim (Taiwan) (TW)
- Boehringer Ingelheim (Germany) (DE)
- University Clinic Golnik, University of Ljubljana, Ljubljana, Slovenia
- ORCID
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2019-08-02
- Volume
- 15
- Issue
- 25
- Pages
- 2905-2914
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W2965410028
- Cited by
- 85
- References
- 27
- Citations by year
- 2026: 1 · 2025: 5 · 2024: 4 · 2023: 8 · 2022: 13 · 2021: 21 · 2020: 23 · 2019: 10
- FWCI
- 12.31
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Future Oncology (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DiRROS repository (University of Maribor) (publishedVersion, cc-by-nc-nd)
- Funders
- Boehringer Ingelheim
- AstraZeneca
- Pfizer
- Novartis
- Takeda
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Keywords
- afatinib, osimertinib, EGFR-mutant non-small cell lung cancer, T790M, time to treatment failure, overall survival, EGFR exon 19 deletion, L858R mutation, real-world evidence
- MeSH terms
- Afatinib, Acrylamides, Aniline Compounds, Carcinoma, Non-Small-Cell Lung, Humans, Indoles, Mutation, Pyrimidines, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study. https://app.cochat.ai/papers/10.2217/fon-2019-0346
- The paper
- Hochmair, M. J., Morabito, A., Hao, D., Yang, C.-T., Soo, R. A., Yang, J. C.-H., Gucalp, R., Halmos, B., Wang, L., Märten, A., & Cufer, T. (2019). Sequential Afatinib and Osimertinib in Patients with EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Updated Analysis of the Observational Giotag Study. Future Oncology. https://doi.org/10.2217/fon-2019-0346
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.